Title: 872P - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Authors: TAUBER RFEUERECKER BENEDIKTKNORR KARINABEHESHTI ASEIDL C.D'ALESSANDRIA CBRUCHERTSEIFER FRANKRETZ MGSCHWEND J.E.WEBER WOLFGANGMORGENSTERN ALFREDEIBER MATTHIAS
Citation: ANNALS OF ONCOLOGY vol. 30 no. S5 p. v342
Publisher: OXFORD UNIV PRESS
Publication Year: 2019
JRC N°: JRC116691
ISSN: 0923-7534 (online)
URI: https://publications.jrc.ec.europa.eu/repository/handle/JRC116691
DOI: 10.1093/annonc/mdz248.029
Type: Articles in periodicals and books
Abstract: The treatment of metastatic castration resistant prostate cancer is still a major medical challenge. The beta-emitting Lu-177-PSMA radioligand therapy (RLT) is a new option but its antitumor effect can decrease over time. The aim of this retrospective analysis was to investigate safety and efficacy of the alpha emitting Ac-225-PSMA-617 RLT in mCRPC after Lu-177-PSMA failure.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.